Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology
The patent extends Pulmatrix's broad protection for its innovative technology to Europe
LEXINGTON, Mass., March 21, 2017 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
"This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases."
- Published: 21 March 2017
- Written by Editor